The Origin of Tissue-Resident Macrophages: When an Erythro-myeloid Progenitor Is an Erythro-myeloid Progenitor  by Gomez Perdiguero, Elisa et al.
Immunity
LettersThe Origin of Tissue-Resident Macrophages:
When an Erythro-myeloid Progenitor
Is an Erythro-myeloid ProgenitorElisa Gomez Perdiguero,1,2 Kay Klapproth,3 Christian Schulz,4 Katrin Busch,3 Marella de Bruijn,5
Hans-Reimer Rodewald,3,* and Frederic Geissmann2,6,*
1CNRS URA 2578, Institut Pasteur, 25–28 Rue du Docteur Roux, Paris 75015, France
2King’s College London, Great Maze Pond, SE1 1UL London, UK
3Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
4Ludwig-Maximilians-Universita¨t Mu¨nchen, Großhadern Campus, Marchioninistraße 15, 81377 Munich, Germany
5Weatherall Institute of Molecular Medicine, University of Oxford and John Radcliffe Hospital, Oxford OX3 9DS, UK
6Memorial Sloan Kettering Cancer Center, 417 East 68th Street, New York, NY 10065, USA
*Correspondence: hr.rodewald@Dkfz-Heidelberg.de (H.-R.R.), geissmaf@mskcc.org (F.G.)
http://dx.doi.org/10.1016/j.immuni.2015.11.022Sheng, Ruedl, and Karjalainen published
in Immunity (Sheng et al., 2015) a fate-
mapping model where the expression of
Cre recombinase was inducible in Kit-ex-
pressing cells (Kit-MeriCreMer mice). In
this system, the authors also revisited
the origin of adult tissue-resident macro-
phages. For a long time, these macro-
phages have been assumed to be mono-
cyte derivatives and hence ultimately to
originate from adult bone marrow stem
cells. In recent years, this view has been
completely revised by the work of several
groups (Schulz et al., 2012; Hashimoto
et al., 2013), and in the field there is now
a view that resident macrophages in
most tissues do not arise from adult he-
matopoietic stem cells (HSCs) but rather
develop at pre-natal stages and persist
autonomously in adult tissues (at least un-
der steady-state conditions). However,
the precise cell of origin for tissue-resi-
dent macrophages during embryonic life
(stages up to approximately day 10 of pre-
natal development) or fetal life (stages
from approximately day 10 of prenatal
development to birth) has been unknown
until recently.
On the basis of fate mapping using
several independent inducible and consti-
tutive mouse models, we recently tracked
the stage of origin of tissue-resident mac-
rophages to times prior to embryonic day
10.5 (E10.5) in development and reported
the identification of yolk-sac-derived er-
ythro-myeloid progenitors (EMPs) as the
main source of fetal and adult tissue-
resident macrophages (Gomez Perdi-
guero et al., 2015). A subsequent report
confirmed our findings that yolk-sac-
derived EMPs are the origin of tissuemac-rophages and further suggested that
macrophages arise either directly from
EMPs or later from fetal monocytes that
are, however, also derived from EMPs
(Hoeffel et al., 2015).
Sheng et al. (2015) now challenge these
two reports by claiming that tissue-resi-
dent macrophages do not originate from
yolk-sac-derived EMPs but, instead, arise
from HSCs that develop independently
from the yolk sac in the embryo or its fetal
liver. They base their claim essentially on
two findings. The first is that in their Kit-
driven fate-mapping system, they failed
to label tissue-resident macrophages
(with the exception of microglia) when
they injected tamoxifen on E7.5. In con-
trast, using Tie2-driven fate mapping, we
found the highest frequencies of fate-
mapped cells whenwe injected tamoxifen
on this very same day (E7.5) (Gomez
Perdiguero et al., 2015). This difference
simply reflects the fact that Tie2 labels he-
mogenic endothelial cells, whereas Kit+
EMPs appear at E8.25 (McGrath et al.,
2015). Consequently, E7.5 yolk sac cells,
including those that give rise to tissue-
resident macrophages, can be genetically
marked by Tie2-MerCreMer but not by
Kit-MeriCreMer, which is exactly what
Sheng, Ruedl, and Karjalainen found.
The second argument Sheng, Ruedl, and
Karjalainen put forward to back up their
claim that yolk-sac-derived EMPs are
not the progenitors of tissue-resident
macrophages is a flow cytometric anal-
ysis of cells included in their Kit-driven
fate mapping. In mice receiving tamoxifen
on E7.5, they detected (in analysis on
E10.5) in the yolk sac marked cells that
they thought were EMPs. Their argumentImmunity 43, Dedeveloped to say that if EMPs but not
tissue-resident macrophages are labeled
on E7.5, then this dissociation shows
that EMPs cannot be the progenitors of
tissue-resident macrophages. We could
subscribe to this conclusion if the cells
analyzed by Sheng et al. indeed qualified
as EMPs. However, these cells fall
short of satisfying many well-established
EMP criteria. First, EMPs are character-
ized by expression of KIT, CD41, CD93
(AA4.1), CD16/32, and CD45 and do not
express SCA1 (McGrath et al., 2015). Of
note, the cells that Sheng et al. consider
to be EMPs have a different phenotype
and hence cannot be the same cells.
Second, in addition to showing cell-sur-
face phenotype, it is essential to demon-
strate that the cells under investigation
have the expected function, i.e., the po-
tential to give rise to both myeloid and
erythoid progeny. In our report, we had
included in-depth in vivo and in vitro func-
tional analyses, including progenitor fre-
quencies for myeloid (M), granulocytic
(G), erythoid (E), and megakaryocytic
(Mk) colonies, as well as mixed G-M and
E-Mk colonies (Gomez Perdiguero et al.,
2015). In brief, both phenotypically and
functionally we had unequivocally identi-
fied the cells as EMPs. Unfortunately,
the study by Sheng et al. (2015) failed by
the same criteria to demonstrate that the
cells that they labeled on E7.5 were
in fact EMPs. Sheng, Ruedl, and Karjalai-
nen state strongly in the title and
summary that, with the exception of
microglia and, partially, epidermal Lang-
erhans cells, most tissue-resident macro-
phages are descendants of classical fetal
HSCs rather than EMPs. For the reasonscember 15, 2015 ª2015 Elsevier Inc. 1023
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Lettersoutlined above, we believe that their pub-
lished data do not support this claim.
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